Plain-English translation of NCT05427383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new drug called KN026 given together with standard chemotherapy for people with advanced stomach cancer that has spread or cannot be surgically removed. The cancer must be a specific type (HER2-positive) and must not have responded to a first-line treatment that included a drug called trastuzumab. The study will happen in two stages: first, researchers will check if the medication is safe and how well it works; then, they will compare it head-to-head against a placebo to see if it helps people live longer.
People whose stomach cancer doesn't respond to standard first-line treatments have very few options left. This trial is exploring whether this new medication might give patients another effective choice and potentially help them survive longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive intravenous infusions of either the new medication (KN026) or a placebo, combined with one of three chemotherapy drugs (your doctor will choose which one), every 3 weeks. You will need to visit the clinic regularly for treatment infusions, blood tests, and imaging scans to monitor how your cancer is responding. The trial has two phases: in the first phase, researchers focus on safety and how well the medication works; in the second phase, you will be randomly assigned to receive either the real medication or placebo combined with chemotherapy, and researchers will track how long you and other participants survive.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China